EUCTR2013-001250-10-GR进行中（未招募）1 期
Safety and Efficacy assessment of Monoprost® (unpreserved latanoprost) in comparison with Lumigan® 0.01 % and Lumigan® 0.03% UD, in patients with open angle glaucoma or ocular hypertension, stabilized by all prostaglandin (except Monoprost®) with ocular surface intolerance.Phase IV, international, multicentre, randomised, investigator masked, 3 months duration, 3 parallel groups, 3 X 120 evaluable patients
aboratoires Thea0 个研究点目标入组 385 人开始时间: 2015年6月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 385
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients will be eligible for inclusion if all these criteria are respected:
- •[1.1]Male or female aged =18 years old.
- •[1.2]Written informed consent.
- •[1.3]Association of the 3 following criteria:
- •[1.3.1] Both eyes have been treated and controlled for at least three months with monotherapy of all prostaglandin (except Monoprost), and have a diagnosis of one of the following:
- •Primary Open Angle Glaucoma or OHT
- •Exfoliative glaucoma or OHT with exfoliative syndrome
- •Pigmentary glaucoma or OHT with pigment dispersion syndrome
- •[1.3.2] IOP = 18 mm Hg in BOTH eyes.
- •[1.3.3]With local intolerance signs in at least one eye defined by the association of:
- •[1.3.3.1]Hyperaemia = Grade (2) or (3) or (4) following the photographic McMonnies scale (0 to 5).
- •[1.3.3.2.1]Presence of at least 2 symptoms with a level of severity = 1 (= mild or moderate or severe) among the following 5 symptoms: irritation / burning, itching, tearing, eye dryness sensation, foreign body sensation.
- •[1.3.3.2.2]Presence of at least 2 signs with a level of severity = 1 (= mild or moderate or severe) among the following 3 signs: superficial punctate keratitis, blepharitis, eyelid skin darkness.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 317
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 79
排除标准
- •Ophthalmic exclusion criteria (in either eye) [2.1]
- •[2.1.1]Presence of at least one severe objective sign among the following:
- •[2.1.1.1]Global ocular staining with Oxford (0-15) grading scheme >12.
- •[2.1.1.2]Blepharitis (Grade 4: very severe, i.e. Eczematiform lesion).
- •[2.1.2]Any secondary glaucoma/OHT (except when associated with exfoliative syndrome or pigment dispersion syndrome), any congenital glaucoma or any angle-closure glaucoma/OHT.
- •[2.1.3]Visual field not performed or not available within the 6 months before inclusion visit.
- •[2.1.4]Fundus not performed or not available within the 6 months before inclusion visit.
- •[2.1.5]Advance stage of glaucoma:
- •[2.1.5.1]Absolute defect in the 10 degrees central point of the visual field.
- •[2.1.5.2]Severe visual field loss according to the investigator’s bestjudgement.
- •[2.1.5.3]Risk of visual field worsening as a consequence of participation in the trial according to the investigator’s best judgement.
- •[2.1.6]Best far corrected visual acuity = 1/10.
- •[2.1.7]History of traumatism, infection, inflammation within the 3 months before inclusion visit.
- •[2.1.8]Ongoing or known history of ocular allergy and/or uveitis and / or viral infection.
- •[2.1.9]Severe dry eye (defined by severe epithelial erosions of the cornea and / or use of dry eye medication with a frequency exceeding 8 instillations / day).
- •[2.1.10]Corneal ulceration.
- •[2.1.11]Palpebral abnormalities not related to medical treatment study and incompatible with a good evaluation.
- •[2.1.12]Any abnormality preventing accurate assessment e.g. reliable tonometry measurement, visual field examination.
- •[2.1.13] Non-responder to latanoprost according to the medical history.
- •The protocol also defines other exclusion criteria such as systemic/non ophthalmic exclusion criteria, specific exclusion criteria for women, exclusion criteria related to general conditions and exclusion criteria related to previous and concomitant medications / non-product therapies.
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the tolerance and efficacy of Monoprost in patients with Glaucoma or Ocular Hypertension, stabilized with Lumigan with signs of ocular surface intoleranceglaucoma, ocular hypertensionMedDRA version: 16.0Level: HLGTClassification code 10018307Term: Glaucoma and ocular hypertensionSystem Organ Class: 10015919 - Eye disordersEUCTR2013-001250-10-ESaboratoires Thea396
进行中（未招募）
1 期
Evaluation of the tolerance and efficacy of Monoprost in patients with Glaucoma or Ocular Hypertension, stabilized by all prostaglandin (except Monoprost®) with signs of ocular surface intolerance.EUCTR2013-001250-10-DEaboratoires Thea396
进行中（未招募）
1 期
Evaluation of the tolerance and efficacy of Monoprost in patients with Glaucoma or Ocular Hypertension, stabilized with Lumigan or Xalatan with signs of ocular surface intoleranceglaucoma, ocular hypertensionMedDRA version: 17.0 Level: HLGT Classification code 10018307 Term: Glaucoma and ocular hypertension System Organ Class: 10015919 - Eye disordersEUCTR2013-001250-10-GBaboratoires Thea396
进行中（未招募）
不适用
Evaluation of the tolerance and efficacy of Monoprost in patients with Glaucoma or Ocular Hypertension, stabilized with Lumigan with signs of ocular surface intoleranceglaucoma, ocular hypertensionMedDRA version: 18.0Level: HLGTClassification code 10018307Term: Glaucoma and ocular hypertensionSystem Organ Class: 10015919 - Eye disordersEUCTR2013-001250-10-FRaboratoires Thea396
已完成
4 期
Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit DosePrimary Open Angle GlaucomaOcular HypertensionNCT02017327Laboratoires Thea379